Search research articles
Contact Us
Filters
Showing results (1-10 of 99) with videos related to
Page
of 10
Sort By:
Statistics in Medicine
|
February 25, 2016
Identifying a maximum tolerated contour in two-dimensional dose finding
Nolan A Wages
Statistics in Medicine
|
December 11, 2014
Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar
Nolan A Wages
Clinical Trials (London, England)
|
June 27, 2017
A web application for evaluating Phase I methods using a non-parametric optimal benchmark
Nolan A Wages, Nikole Varhegyi
Journal of Biopharmaceutical Statistics
|
June 7, 2014
Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents
Nolan A Wages, Christopher Tait
Computer Methods and Programs in Biomedicine
|
July 23, 2013
pocrm: an R-package for phase I trials of combinations of agents
Nolan A Wages, Nikole Varhegyi
Clinical Trials (London, England)
|
September 25, 2019
Evaluation of irrational dose assignment definitions using the continual reassessment method
Nolan A Wages, Evan Bagley
Statistics in Biopharmaceutical Research
|
August 22, 2025
Isotonic Phase I cancer clinical trial design utilizing patient-reported outcomes
Nolan A Wages, Ruitao Lin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2018
Accuracy, Safety, and Reliability of Novel Phase I Designs-Letter
Nolan A Wages, Thomas M Braun
Clinical Trials (London, England)
|
December 21, 2019
Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy
Nolan A Wages, Camilo E Fadul
Pharmaceutical Statistics
|
June 5, 2013
Specifications of a continual reassessment method design for phase I trials of combined drugs
Nolan A Wages, Mark R Conaway
Page
of 10
Search research articles
Search
Showing results (1-10 of 99) with videos related to
Sort By:
Page
of 10
Statistics in Medicine
|
February 25, 2016
Identifying a maximum tolerated contour in two-dimensional dose finding
Nolan A Wages
Statistics in Medicine
|
December 11, 2014
Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar
Nolan A Wages
Clinical Trials (London, England)
|
June 27, 2017
A web application for evaluating Phase I methods using a non-parametric optimal benchmark
Nolan A Wages, Nikole Varhegyi
Journal of Biopharmaceutical Statistics
|
June 7, 2014
Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents
Nolan A Wages, Christopher Tait
Computer Methods and Programs in Biomedicine
|
July 23, 2013
pocrm: an R-package for phase I trials of combinations of agents
Nolan A Wages, Nikole Varhegyi
Clinical Trials (London, England)
|
September 25, 2019
Evaluation of irrational dose assignment definitions using the continual reassessment method
Nolan A Wages, Evan Bagley
Statistics in Biopharmaceutical Research
|
August 22, 2025
Isotonic Phase I cancer clinical trial design utilizing patient-reported outcomes
Nolan A Wages, Ruitao Lin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2018
Accuracy, Safety, and Reliability of Novel Phase I Designs-Letter
Nolan A Wages, Thomas M Braun
Clinical Trials (London, England)
|
December 21, 2019
Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy
Nolan A Wages, Camilo E Fadul
Pharmaceutical Statistics
|
June 5, 2013
Specifications of a continual reassessment method design for phase I trials of combined drugs
Nolan A Wages, Mark R Conaway
Page
of 10